Theravance Inc - THRX - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 12, 2013

Theravance Inc - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
THRX	Nasdaq	2834	http://www.theravance.com/	39.585 +0.045
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Theravance Inc The Billion Dollar COPD Deal: Who Gains The Most? - May 17th, 2013 9:27 am A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical Companies - May 16th, 2013 1:39 pm THERAVANCE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - May 16th, 2013 7:30 am Theravance's CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) - May 15th, 2013 5:26 pm Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companies - May 15th, 2013 11:42 am Elan in Royalty Deal with THRX - May 14th, 2013 2:00 pm Analysts: BlackBerry’s MDM Is Underappreciated and 3 More Research Notes to Read - May 14th, 2013 12:04 pm Today's Market News To Trade On: 5 Stocks Moving On News - May 14th, 2013 7:06 am Who Benefits From This Market Moving Biotechnology Partnership? - May 14th, 2013 6:44 am Theravance price target raised to $48 from $38 at RW Baird - May 14th, 2013 6:16 am Do These Top Stock Picks Have More Room to Grow? - May 13th, 2013 4:06 pm Diversifying Royalties at a Hefty Cost - May 13th, 2013 3:40 pm Glaxo/THRX's Breo Ellipta Gets FDA Nod - May 13th, 2013 3:20 pm Post Holdings, Tesla, Overstock.com are big movers - May 13th, 2013 3:14 pm Post Holdings, Tesla, Overstock.com are big movers - May 13th, 2013 3:14 pm Stocks Finish Flat as Earnings Wind Down - May 13th, 2013 3:13 pm Blue Chips Decline - May 13th, 2013 2:37 pm Why Did This Biotech Soar? - May 13th, 2013 2:28 pm Elan to Pay $1 Billion for Stake in Theravance Royalties - May 13th, 2013 2:17 pm Billionaire Seth Klarman's Long-Term Stock Picks - May 13th, 2013 2:04 pm View All Current Headlines >>